New oral anticoagulants after acute coronary syndrome

被引:0
|
作者
Bennaghmouch, N. [1 ]
ten Berg, J. M. [1 ]
机构
[1] St Antonius Hosp Nieuwegein, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
关键词
antithrombins; anticoagulants; acute coronary syndrome; secondary prevention; factor Xa; thrombin; humans; ELEVATION MYOCARDIAL-INFARCTION; FACTOR XA INHIBITOR; LOWER CARDIOVASCULAR EVENTS; DUAL ANTIPLATELET THERAPY; DOUBLE-BLIND; ATRIAL-FIBRILLATION; ST-ELEVATION; SYNDROME-THROMBOLYSIS; SECONDARY PREVENTION; STANDARD THERAPY;
D O I
10.1016/j.beha.2013.07.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New oral anticoagulants (NOACs) have been developed that may further decrease the mortality and morbidity of ACS by complementing antiplatelet therapy. Optimal use of these agents can be achieved by maximum reduction in thrombotic events at the minimum bleeding risk when combining a long-term oral anticoagulant with anti-platelet therapy in patients with coronary heart disease. Although, based on the pharmacokinetics and -dynamics of NOACs, these agents could improve the current management of ACS patients, multiple trials consistently demonstrate a trend toward increased major and clinically relevant non major bleeding almost diminishing the benefits in reduction of ischemic events. Therefore, some critical issues need to be further evaluated in future trials. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:141 / 150
页数:10
相关论文
empty
未找到相关数据